NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia in adults

21 June 2024 - Kyowa Kirin is delighted by the decision made today by NICE to recommend Crysvita for the treatment ...

Read more →

Outcomes from the May 2024 PBAC intracycle meeting

21 June 2024 - Recommendations made by the PBAC in May 2024 relating to the listing of medicines on the PBS ...

Read more →

Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy (final guidance)

19 June 2024 - NICE has published final evidence-based recommendations on the use of tafamidis meglumine (Vyndaqel) for the treatment ...

Read more →

Baricitinib for the treatment of patients with juvenile idiopathic arthritis

13 June 2024 - NICE is unable to make a recommendation on the use in the NHS of baricitinib (Olumiant) for ...

Read more →

Pembrolizumab in combination with trastuzumab and chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma (final guidance)

12 June 2024 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with trastuzumab and ...

Read more →

Voxelotor for the treatment of patients with haemolytic anaemia caused by sickle cell disease

12 June 2024 - NICE has published final evidence-based recommendations on the use of voxelotor (Oxbryta) for the treatment of ...

Read more →

SMC - June 2024 decisions

10 June 2024 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...

Read more →

Nivolumab for the adjuvant treatment of patients 12 years and older with completely resected melanoma at high risk of recurrence

5 June 2024 - NICE is unable to make a recommendation on the use of nivolumab (Opdivo) for the adjuvant treatment ...

Read more →

Mounjaro is second obesity drug to be approved for use in England

4 June 2024 - Those with BMI of at least 35 kg.m2 and a co-morbidity can now be prescribed tirzepatide and ...

Read more →

Zanubrutinib in combination with obinutuzumab for the treatment of patients with relapsed or refractory B-cell follicular lymphoma after two or more treatments

28 May 2024 - NICE is unable to make a recommendation on the use of zanubrutinib (Brukinsa) in combination with obinutuzumab ...

Read more →

Dabrafenib mesylate in combination with trametinib dimethyl sulphoxide for the treatment of children and adolescents with BRAF V600E mutation positive glioma

29 May 2024 - NICE has published final evidence-based recommendations on the use of dabrafenib mesylate (Finlee) in combination with ...

Read more →

Trastuzumab deruxtecan for the treatment of patients with advanced HER2 mutation positive non-small-cell lung cancer after platinum-based chemotherapy

29 May 2024 - NICE is unable to make a recommendation on the use of trastuzumab deruxtecan (Enhertu) for the treatment ...

Read more →

Setmelanotide acetate for the treatment of patients with obesity and hyperphagia in Bardet-Biedl syndrome (final guidance)

22 May 2024 - NICE has published final evidence-based recommendations on the use of setmelanotide acetate (Imcivree) for treating obesity ...

Read more →

Sirolimus for the treatment of patients with facial angiofibroma caused by tuberous sclerosis complex

22 May 2024 - NICE is unable to make a recommendation on the use of sirolimus (Hyftor) for the treatment of ...

Read more →

Tisagenlecleucel for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukaemia

15 May 2024 - NICE has published final evidence-based recommendations on the use of tisagenlecleucel (Kymriah) for the treatment of ...

Read more →